Biochem/physiol Actions

Cell permeable: no

Reversible: no

Product does not compete with ATP.

Primary TargetAnticancer, antiviral agent that is especially effective against leukemias

General description

Anticancer, antiviral agent that is especially effective against leukemias. Induces apoptosis in human myeloid leukemia cells and in rat sympathetic neurons. Induces G₁/S phase cell cycle arrest.

Cytosine analog that acts as a potent inhibitor of eukaryotic cellular and viral replicative DNA synthesis. AraCTP, formed by intracellular phosphorylation of AraC, is utilized as a substrate by DNA polymerases, which incorporate AraCMP residues into DNA. Incorporated 3′-terminal AraCMP residues inhibit further DNA synthesis by impeding chain elongation by DNA polymerase. AraC is used clinically in the treatment of various cancers, particularly leukemias and lymphomas. Also used to inhibit proliferation of cultured cells and replication of eukaryotic viruses (e.g. vaccinia virus, herpes simplex virus). Also shown to induce apoptosis in human myeloid leukemia cells and in post-mitotic rat sympathetic neurons.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Zarilli, R., et al. 1999. Gastroenterology 116, 1358.Dessi, F., et al. 1995. J. Neurochem.64, 1980.Grant, S., et al. 1994. Oncol. Res. 6, 87.Greenberg, A.L., et al. 1994. Cancer74, 1261.Perrino, F.W., et al. 1997. J. Biol. Chem.269, 16357.Tomkins, C.E., et al. 1994. J. Cell Sci.107, 1499.Taddie, J.A., and Traktman, P. 1993. J. Virol.67, 4323.Brach, M.A., et al. 1992. Mol. Pharmacol.41, 60.Este, E., et al. 1992. Blood79, 2246.Owens, J.K., et al. 1992. Cancer Res.52, 2389.

Packaging

1 g in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 6 months at -70°C.

Warning

Toxicity: Harmful & Carcinogenic / Teratogenic (E)